Skip to main content

Table 1 Baseline clinical characteristics, choice of treatment, and adverse events of patients with EGFR-WT and EGFR-mutant NSCLC

From: Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

Variable

Total population

(N = 28)

EGFR-WT

(N = 13)

EGFR-mutant

(N = 15)

P

 Sex, no. (%)

   

0.13

 • Male

14 (50)

4 (30.7)

10 (66.6)

 

 • Female

14 (50)

9 (69.2)

5 (33.3)

 

Age (years)

   

0.77

 • Mean ± SD

63.6 ± 8.8

63.0 ± 9.7

64.0 ± 8.2

 

BW (kg)

   

0.28

 • Median

50.3

50.7

50

 

 • Range

42—76

45—76

(42—76)

 

 BMI (kg/m2), no. (%)

   

0.43

 • Underweight (<18.5)

3 (10.7)

0 (0)

3 (20.0)

 

 • Normal (18.5–22.9)

13 (46.4)

6 (46.1)

7 (46.6)

 

 • Overweight (23–24.9)

6 (21.4)

4 (30.7)

2 (13.3)

 

 • Obese (> 25)

6 (21.4)

3 (23.0)

3 (20.0)

 

WHO performance status (ECOG), no. (%)

   

0.69

 • 0

7 (25.0)

2 (15.3)

5 (33.3)

 

 • 1

19 (67.8)

10 (76.9)

9 (60.0)

 

 • 2

2 (7.1)

1 (7.6)

1 (6.6)

 

Smoking status, no. (%)

   

0.48

 • Never-smoker

20 (71.4)

10 (76.9)

10 (66.6)

 

 • Ex-smoker

5 (17.8)

1 (7.6)

4 (26.6)

 

 • Current smoker

3 (10.7)

2 (15.3)

1 (6.67)

 

Underlying disease, no. (%)

    

 • Diabetes mellitus

5 (17.8)

3 (23.0)

2 (13.3)

0.64

 • Hypertension

12 (42.8)

6 (46.1)

6 (40.0)

0.74

 • Dyslipidemia

7 (25.0)

1 (7.6)

6 (40.0)

0.08

 • Chronic obstructive pulmonary disease

0 (0)

0 (0)

0 (0)

 

 • Inflammatory bowel disease

0 (0)

0 (0)

0 (0)

 

Previous GI tract surgery, no. (%)

1 (3.5)

0 (0)

1 (6.6)

> 0.99

Drug use in past 4 weeks, no. (%)

    

 • Antibiotics

3 (10.7)

2 (15.3)

1 (6.6)

0.58

 • Proton pump inhibitors

5 (17.8)

1 (7.6)

4 (26.6)

0.33

 • Laxatives

8 (28.5)

4 (30.7)

4 (26.6)

> 0.99

 • Prebiotics/probiotics

8 (28.5)

3 (23.0)

5 (33.3)

0.69

 • Supplement

4 (14.2)

2 (15.3)

2 (13.3)

0.78

Non-small cell lung cancer

Histologic subtype, no. (%)

   

0.21

 • Adenocarcinoma

25 (85.2)

11 (84.6)

14 (93.3)

 

 • Squamous cell carcinoma

2 (7.1)

2 (15.3)

0 (0)

 

 • Adenosquamous cell carcinoma

1 (3.5)

0 (0)

1 (6.67)

 

Stage at diagnosis, no. (%)

   

0.82

 • IIIb

1 (3.5)

0 (0)

1 (6.6)

 

 • IIIc

2 (7.1)

1 (7.6)

1 (6.6)

 

 • IVa

19 (67.8)

10 (76.9)

9 (60.0)

 

 • IVb

6 (21.4)

2 (15.3)

4 (26.6)

 

Albumin (g/dL), no. (%)

   

0.02

 < 3.2

 ≥ 3.2

12 (42.8)

16 (57.1)

9 (69.2)

4 (30.7)

3 (20.0)

12 (80)

 

EGFR status, no. (%)

    

 • Wild-type

 

13 (100)

0 (0)

 

 • Exon 19 deletion

  

8 (53.3)

 

 • Exon 21 L858R

  

5 (33.3)

 

 • Uncommon mutations

(G719X, S768I, L861Q)

  

2 (13.3)

 

Treatment regimen, no. (%)

    

 • Carboplatin/paclitaxel

 

13 (100)

  

 • Gefitinib

  

4 (26.6)

 

 • Erlotinib

  

4 (26.6)

 

 • Osimertinib

  

2 (13.3)

 

 • Others

  

5 (33.3)

 

Adverse events, no. (%)

   

0.66

 Grade< 2

 Grade≥ 2

12 (42.8)

16 (57.1)

5 (38.4)

8 (61.5)

7 (46.6)

8 (53.3)

 
  1. BMI Body mass index, BW Body weight, EGFR Epidermal growth factor receptor, GI Gastrointestinal, WHO World Health Organization